Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
| Last: | $29.84 |
|---|---|
| Change Percent: | 4.37% |
| Open: | $29.35 |
| Close: | $28.59 |
| High: | $30.08 |
| Low: | $29.09 |
| Volume: | 28,109 |
| Last Trade Date Time: | 02/27/2026 12:26:38 pm |
| Market Cap: | $1,346,118,602 |
|---|---|
| Float: | 30,701,034 |
| Insiders Ownership: | 0.05% |
| Institutions: | 34 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.rapportrx.com |
| Country: | US |
| City: | Boston |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Rapport Therapeutics Inc. (NASDAQ: RAPP).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.